An observational study in Infertility, Female and Fertility Disorders, sponsored by Clinica de la Mujer Medicina Reproductiva, Chile. Completed. Open to female participants aged 21 Years to 30 Years. Per ClinicalTrials.gov, last updated 2022-10-13.
Sponsored by Clinica de la Mujer Medicina Reproductiva, Chile · Observational
Prospective controlled study to assess the reproductive outcomes of OD recipients in which the donors were subjected to the DYG protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm. The OD cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter >18mm.
552 studies on the registry are indexed under Infertility, Female; 137 are open to participants now.
This study's planned enrollment of 202 is above the median of 161 across 162 observational studies indexed under Infertility, Female.
Browse Infertility, Female studies →Clinica de la Mujer Medicina Reproductiva, Chile is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Oocyte donors undergoing controlled ovarian stimulation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oocyte donors undergoing controlled ovarian stimulation in a progestin-primed ovarian stimulation protocol with DYG protocol (20mg/day)
Drug: Dydrogesterone
oocyte donors undergoing controlled ovarian stimulation in a GnRH antagonist protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm
progestin primed ovarian stimulation
Live Birth Rate per transfer
Time frame: 40 weeks after ET
Clinical pregnancy per transfer
Time frame: 12 weeks after ET
Miscarriage rate
Time frame: 12 weeks after ET
Number of oocytes retrieved
Time frame: at time of oocyte retrieval
Number of mature oocytes
Time frame: 1 day after IVF
Number of fertilized oocytes
Time frame: 1 day after IVF
Number of blastocists
Time frame: 5-6 days after OPU
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Dec 2021, 59 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinica de la Mujer Medicina Reproductiva, Chile